Carcidiag, to better target cancer treatments

Yann Hamon
changed to

4:52 p.m., June 14, 2022

With its Future Trophies, Europe 1 rewards companies, associations or local authorities each year for their audacity, their innovation and their visionary side. In the running for the Health Trophy, in partnership with Arthrtitis-Clarins, Carcidiag is developing prognosis kits for cancer in order to ensure a better cost.

Carcidiag has developed a range of prognosis kits for cancer in patients already affected. These kits make it possible to define the aggressiveness of cancers in order to determine personalized care for each patient under treatment.

Research and development

All of the Carcidiag prognostic kits for oncologists and pathologists have been on the market since the beginning of 2022, after a period of more than three years for research and development.

Towards a better life expectancy

“Based on a biopsy performed on affected patients, the kits will provide additional information that is essential for the proper care of patients. For example, patients with lung cancer at an early stage will be able to have access to complementary treatments by fertilization or radiotherapy; whereas they would have, until now, only had access to surgery”, we detail Vincent Carré, president of Carcidiag. This price in charge will allow a better life expectancy of patients affected by cancer.


Not all news on the site expresses the point of view of the site, but we transmit this news automatically and translate it through programmatic technology on the site and not from a human editor.
Back to top button